Metoclopramide

How to order Metoclopramide

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Metoclopramide on Prescriptsy

Metoclopramide is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Metoclopramide is an antiemetic and prokinetic medicine used to prevent and treat nausea and vomiting in adults and adolescents.

It has been available in the United Kingdom since the 1960s and remains one of the most commonly prescribed antiemetic agents, particularly for short-term management of nausea and vomiting associated with migraine, post-operative states, chemotherapy, and gastroparesis.

Metoclopramide is available as tablets (10 mg), oral solution, and injection.

It is a prescription-only medicine (POM) and is subject to a maximum treatment duration of 5 days, following a safety review by the European Medicines Agency (EMA) and MHRA that identified a significant risk of neurological adverse effects with prolonged use.

Nausea and vomiting are among the most common symptoms seen in primary and secondary care.

They can result from a wide range of causes, including gastrointestinal disorders, infections, medicines, post-operative states, pregnancy, chemotherapy, radiotherapy, and neurological conditions such as migraine.

Effective antiemetic therapy improves patient comfort, prevents complications such as dehydration and electrolyte imbalance, and can enhance the effectiveness of other treatments (for example, metoclopramide improves analgesic absorption during migraine attacks).

This page provides a detailed clinical overview of metoclopramide, covering its mechanism of action, current prescribing restrictions, dosage guidance, side effects, safety warnings, and practical information for patients in the United Kingdom.

Important safety information about metoclopramide

• Metoclopramide must not be used for more than 5 days, as prolonged use increases the risk of serious neurological side effects including tardive dyskinesia.
• The maximum recommended dose is 10 mg up to three times daily (maximum 30 mg daily).
• Extrapyramidal reactions (involuntary muscle movements) can occur, particularly in young adults. Stop taking metoclopramide and seek medical advice immediately if you experience unusual muscle stiffness, spasms, or involuntary movements.
• Metoclopramide is not recommended for children under 15 years of age except under specialist guidance.
• This medicine may cause drowsiness. Do not drive or operate machinery if affected.

Understanding the EMA/MHRA restriction on metoclopramide

In 2013, the EMA completed a review of metoclopramide across all EU member states following long-standing concerns about neurological adverse effects.

The review concluded that the benefits of metoclopramide continued to outweigh its risks for short-term use at standard doses, but the risk of acute extrapyramidal reactions and tardive dyskinesia increased substantially with higher doses and prolonged treatment.

As a result, the recommended maximum treatment duration was restricted to 5 days, maximum single and daily doses were reduced, and use in children under 1 year was contraindicated.

The MHRA adopted these changes into UK prescribing practice. These restrictions remain in force and are reflected in the current Summary of Product Characteristics (SmPC) and BNF recommendations.

How metoclopramide works: mechanism of action

Metoclopramide exerts its antiemetic and prokinetic effects through several pharmacological actions.

The primary mechanism is dopamine D2 receptor antagonism at two key sites: the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem, and the upper gastrointestinal tract.

The CTZ lies outside the blood-brain barrier and detects emetogenic stimuli in the blood (toxins, drugs, metabolic products).

By blocking dopamine receptors in the CTZ, metoclopramide suppresses the vomiting reflex.

In the gastrointestinal tract, metoclopramide blocks inhibitory dopamine D2 receptors on myenteric neurons, which enhances acetylcholine release and increases smooth muscle motility.

This accelerates gastric emptying, increases lower oesophageal sphincter pressure, and improves coordinated peristalsis in the upper gut.

These prokinetic effects are particularly useful in conditions involving gastroparesis (delayed stomach emptying), such as diabetic gastroparesis and migraine-associated gastric stasis.

At therapeutic doses, metoclopramide also has some 5-HT3 receptor antagonist activity (contributing to its antiemetic effect) and weak 5-HT4 receptor agonist activity (contributing to its prokinetic effect).

However, its activity at serotonin receptors is less potent than that of dedicated 5-HT3 antagonists such as ondansetron.

Clinical evidence and indications

Metoclopramide is licensed in the UK for the prevention and treatment of nausea and vomiting, including delayed chemotherapy-induced nausea and vomiting (CINV) and radiotherapy-induced nausea and vomiting as a second-line option, post-operative nausea and vomiting (PONV), and symptomatic treatment of nausea and vomiting including that associated with acute migraine (where it may also be used to improve the absorption of oral analgesics).

For migraine-associated nausea, metoclopramide serves a dual purpose: it treats the nausea itself and restores normal gastric emptying, which is frequently impaired during migraine attacks (gastric stasis).

This restoration of gut motility improves the absorption and onset of action of co-administered analgesics such as paracetamol and aspirin.

The BNF and NICE Clinical Knowledge Summaries support the use of metoclopramide in adult migraine as an adjunct to analgesics.

For gastroparesis, metoclopramide can provide short-term symptom relief by accelerating gastric emptying. However, the 5-day treatment limit restricts its usefulness for chronic gastroparesis, and alternative approaches (dietary modifications, domperidone, erythromycin) may be more appropriate for long-term management.

Metoclopramide compared with other antiemetics

Several antiemetic agents are available in the UK, and the choice depends on the cause and severity of nausea and vomiting, patient factors, and the side effect profile.

Domperidone is another dopamine D2 antagonist with similar prokinetic effects but does not cross the blood-brain barrier as readily as metoclopramide, resulting in a lower risk of extrapyramidal reactions.

However, domperidone carries a small risk of serious cardiac arrhythmia and QT prolongation, and the MHRA advises using the lowest effective dose for the shortest possible time.

Ondansetron is a 5-HT3 receptor antagonist widely used for CINV and PONV.

It is highly effective for acute vomiting but does not have prokinetic activity and commonly causes constipation.

Cyclizine is an antihistamine antiemetic used for motion sickness, labyrinthine disorders, and PONV.

It has anticholinergic side effects (dry mouth, blurred vision, drowsiness) and is less effective for chemotherapy-induced nausea.

Prochlorperazine is a phenothiazine antiemetic with dopamine-blocking activity, commonly used for nausea, vertigo, and labyrinthitis. It carries a risk of extrapyramidal effects similar to metoclopramide.

Dosage and administration

For adults, the recommended dose is 10 mg up to three times daily, with a minimum interval of 6 hours between doses.

The maximum daily dose is 30 mg or 0.5 mg/kg body weight, whichever is lower.

When used for nausea associated with migraine, a single 10 mg dose is usually sufficient.

Tablets should be taken 30 minutes before meals if used for gastroparesis or meal-related nausea. Treatment must not exceed 5 days.

In renal impairment, dose reduction is required: reduce by 50% if the eGFR is between 15 and 60, and by 75% if below 15.

In severe hepatic impairment, reduce the dose by 50%. Elderly patients should use the lowest effective dose due to increased sensitivity to adverse effects.

Side effects of metoclopramide

Extrapyramidal reactions

Acute dystonic reactions occur in approximately 1 in 500 patients and are more common in young adults (particularly women), children, and when higher doses are used.

They typically present within 24 to 48 hours of starting treatment as involuntary sustained muscle contractions, particularly affecting the muscles of the face, neck, and tongue (oculogyric crisis, torticollis, trismus).

These reactions are distressing but usually reversible with anticholinergic treatment (procyclidine injection). Akathisia (motor restlessness) and drug-induced parkinsonism (tremor, rigidity, shuffling gait) may also occur.

Tardive dyskinesia

Tardive dyskinesia involves involuntary repetitive movements of the face, lips, tongue, jaw, and occasionally the trunk and limbs. Unlike acute dystonia, tardive dyskinesia may be irreversible.

The risk is highest with prolonged use (weeks to months), higher doses, elderly patients, and women. The 5-day treatment restriction was introduced specifically to reduce this risk.

Other side effects

Drowsiness, fatigue, and restlessness are common. Elevation of prolactin levels can cause galactorrhoea, menstrual irregularities, gynaecomastia, and sexual dysfunction. These effects resolve upon stopping the medicine.

Diarrhoea, headache, and dizziness are reported occasionally.

Rare but serious effects include neuroleptic malignant syndrome (high fever, muscle rigidity, altered consciousness), cardiac QT prolongation (particularly with IV administration), and methaemoglobinaemia.

When to seek urgent medical advice

Stop metoclopramide and seek immediate medical attention if you experience involuntary muscle spasms or abnormal movements (particularly of the face, neck, or tongue), high fever with muscle stiffness and confusion (possible neuroleptic malignant syndrome), or an allergic reaction (swelling of the face, lips, or throat, difficulty breathing).

Call 999 in an emergency. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Metoclopramide is contraindicated in phaeochromocytoma, gastrointestinal obstruction, perforation or haemorrhage, epilepsy (or patients at risk of seizures, as metoclopramide lowers the seizure threshold), Parkinson's disease, and known hypersensitivity. It must not be used with other dopamine antagonists concurrently.

Age-specific cautions

Children under 15 are at higher risk of extrapyramidal reactions and should only receive metoclopramide under specialist supervision. Elderly patients are more susceptible to tardive dyskinesia and should use the lowest effective dose for the shortest duration.

Drug interactions

Avoid concurrent use with other dopaminergic antagonists (antipsychotics, domperidone). Metoclopramide accelerates gastric emptying, which may alter the absorption of co-administered medicines.

It may reduce the plasma concentration of digoxin (absorbed primarily from the stomach) and increase the bioavailability of ciclosporin (absorbed from the small intestine).

Use with levodopa is contraindicated due to mutual antagonism. Opioid analgesics reduce gastric motility and may oppose metoclopramide's prokinetic effects.

Pregnancy and breastfeeding

Limited data on metoclopramide use in pregnancy do not suggest an increased risk of malformation.

It is sometimes used for hyperemesis gravidarum under specialist guidance when other antiemetics have been ineffective. Metoclopramide passes into breast milk.

Short-term use during breastfeeding is sometimes considered acceptable, but galactorrhoea and sedation in the infant are potential concerns. Discuss with your prescriber.

How to get metoclopramide in the UK

Metoclopramide is a prescription-only medicine. You need a prescription from your GP, hospital specialist, or an authorised online prescriber registered with the GPhC.

The NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Sources

• Metoclopramide 10mg Tablets, Summary of Product Characteristics (EMC)
• Metoclopramide hydrochloride, British National Formulary (BNF)
• MHRA Drug Safety Update: Metoclopramide
• Metoclopramide, NHS
• MHRA Yellow Card Scheme